Download  full announ c ement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that CPT reimbursement code 0105U for its  KidneyIntelX™  test has become effective nationally in the United States as of October 1, 2019. 

Download  full announement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it expects to appoint an additional non-executive director and healthcare industry veteran within the coming weeks.

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Centers for Medicare & Medicaid Services (“CMS”) has published its preliminary determination for national Medicare pricing for the

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical  in vitro  diagnostics for kidney disease, confirms that the Annual Report and Accounts for the period ended 30 June 2019  (“2019 Annual Report”), the Notice of the Annual General

Download  full announcement Renalytix AI plc (AIM: RENX), the AIM listed developer of artificial intelligence-enabled diagnostics for kidney disease, announces its inaugural final results for the period ended June 30, 2019. Operational highlights The U.S.

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical  in vitro  diagnostics for kidney disease, announces that it will release its preliminary results for the year ended 30 June 2019 on Tuesday, 3 September 2019.

Download  full announcement Intended appointment of an additional Non-Executive Director Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical  in vitro  diagnostics for kidney disease, announces the expansion of its core investigator group for lead product  KidneyIntelX  ™

Download  full announcement For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2019, the Company’s issued and fully paid share capital consists of 59,416,134 ordinary shares with a nominal value of £0.0025 each (“Ordinary

Download  full announcement RenalytixAI Expands Leadership Team with Focus on Reimbursement ahead of roll-out of artificial intelligence clinical in vitro diagnostic KidneyIntelX  ™ RenalytixAI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces